Dr. Reddy's Laboratories (RDY) reported fiscal Q3 earnings Thursday of $0.20 per diluted share, up from $0.19 a year earlier.
Three analysts polled by FactSet expected $0.21.
Revenue for the quarter ended Dec. 31 was $977 million, compared with $843 million a year earlier.
Analysts surveyed by FactSet expected $950.5 million.
RDY shares were down 5.2% in recent trading.
Price: 14.31, Change: -0.79, Percent Change: -5.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.